Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Ivabradine HCl (Corlentor; Corlanor; Coraxan; Ivabid; Procoralan; Coralan; S16257; S 16257; S-16257; Bradia), the hydrochloride salt of Ivabradine, is a novel and potent cardiac pacemaker current (If) inhibitor with antianginal effects. It suppresses IF with IC50 of 2.9 μM. Ivabradine is a pure heart rate reducer that works exclusively on the sinoatrial node's pacemaker activity. A novel medication called ivabradine is prescribed to treat stable angina pectoris symptomatically. In contrast to beta blockers and calcium channel blockers, two frequently prescribed antianginal medications, ivabradine works by selectively inhibiting the funny channel to lower heart rate.
Targets |
Adrenergic Receptor
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C27H37CLN2O5
|
|
---|---|---|
Molecular Weight |
505.05
|
|
Exact Mass |
504.24
|
|
Elemental Analysis |
C, 64.21; H, 7.38; Cl, 7.02; N, 5.55; O, 15.84
|
|
CAS # |
148849-67-6
|
|
Appearance |
Solid powder
|
|
SMILES |
CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.Cl
|
|
InChi Key |
HLUKNZUABFFNQS-ZMBIFBSDSA-N
|
|
InChi Code |
InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1
|
|
Chemical Name |
3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9800 mL | 9.9000 mL | 19.8000 mL | |
5 mM | 0.3960 mL | 1.9800 mL | 3.9600 mL | |
10 mM | 0.1980 mL | 0.9900 mL | 1.9800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05973591 | Active Recruiting |
N/A | Dilated Cardiomyopathy Ventricular Remodeling |
Yonsei University | July 15, 2023 | N/A |
NCT05882708 | Recruiting | Drug: Ivabradine | Sepsis Ivabradine Hemodynamics |
Second Affiliated Hospital of Guangzhou Medical University |
June 1, 2023 | Phase 4 |
NCT03168529 | Recruiting | Drug: Placebo Drug: Ivabradine |
Heart Failure | Phillip Levy | July 1, 2018 | Phase 4 |
NCT05348057 | Recruiting | Drug: Ivabradine | Cardiovascular Diseases | Qian geng | August 1, 2021 | Phase 4 |
NCT05481177 | Recruiting | Drug: Ivabradine | Long Haul COVID Postural Orthostatic Tachycardia Syndrome |
Uniformed Services University of the Health Sciences |
June 14, 2023 | Phase 4 |